Anti-VEGF (anti-vascular endothelial growth factor) treatment for central vein occlusion during breastfeeding

Groselli, S.; Bechstein, L.; Gabka, K.; Ulbig, M.

doi:10.1007/s00347-022-01694-4

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer, a critical area demanding innovative therapeutic approaches, ranks second among women and third among men in cancer diagnoses [9]. Targeted drug delivery to tumour sites becomes pivotal in cancer therapy, particularly in inhibiting angiogenesis driven by vascular endothelial growth factor (VEGF) [10]. Capecitabine, a prodrug converting to 5-uorouracil in the body, emerges as a potent tool against colorectal cancer, inhibiting thymidylate synthase and halting cancer cell proliferation [11].…”

Section: Introductionmentioning

confidence: 99%

Development and Evaluation of Potato Starch and Chitosan Modified Capecitabine Nanoparticles for Enhanced Colon Cancer Treatment: A Comprehensive Study on PhysicalProperties, In vitro Efficacy, and In vivo Targeting

Bhattacharya,

Page,

Shinde

2024

Preprint

View full text Add to dashboard Cite

This study explores the innovative application of carbohydrate-based nanoparticles in aggressive colon cancer treatment. We synthesized Capecitabine (CTB) nanoparticles by conjugating them with potato starch and chitosan, utilizing the unique properties of these materials. CTB nanoparticles were meticulously fabricated through ultrasonication, hydrolysis with 0.1M NaOH, and ionotropic gelation. Characterization included drug loading, rheological studies, Surface-Enhanced Raman Spectroscopy (SERS), Fourier-Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-ray Diffraction (XRD), and Thermogravimetric Analysis (TGA). Analysis of XRD and FTIR spectra revealed molecular disorder and crystallinity loss. Beyond physical characterization, we explored functional and antioxidant properties, showing promise with a mean particle size of 245±10.45nm, zeta potential +30.3±8.09 mV, leading efficacy 76.45±3.85%, and 92.25±5.78% drug release over 100 hours. Subsequently, we evaluated cytotoxicity against HT-29 cells in vitro and in vivo using N, N-dimethylhydrazine-induced male Balb/c mice. Capecitabine-loaded potato starch-chitosan (CTB-PS-CS) nanoparticles exhibited superior colon histology and lower tumour scores, highlighting their robust anticancer activity. CTB-PS-CS-NPs significantly reduced VEGD and CD31 compared to free CTB. We conducted various cellular assays, including tube-forming, wound-healing, crystal violet staining, and apoptosis studies, consistently demonstrating pronounced anticancer effects on HT-29 cells. Our study supports the enhanced anticancer activity of CTB-PS-CS-NPs, indicating their potential for assessing nanoparticle efficacy and compatibility across diverse cancer models.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and Evaluation of Potato Starch and Chitosan Modified Capecitabine Nanoparticles for Enhanced Colon Cancer Treatment: A Comprehensive Study on PhysicalProperties, In vitro Efficacy, and In vivo Targeting

Bhattacharya,

Page,

Shinde

2024

Preprint

View full text Add to dashboard Cite

show abstract

Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature

Ong,

Kiire,

Frise

et al. 2023

Eye

View full text Add to dashboard Cite

Introduction Anti-vascular endothelial growth factor (anti-VEGF) agents may occasionally need to be considered for sight-threatening macular pathology in pregnant and breastfeeding women. This is controversial due to the dearth of data on systemic side effects for mother and child. We aimed to expand the evidence base to inform management. Methods Retrospective case series of pregnant and breastfeeding women treated with intravitreal anti-VEGF injections at Oxford Eye Hospital between January 2015 and December 2022. In addition, we conducted a systematic review and combined eligible cases in a narrative synthesis. Results We treated six pregnant women with anti-VEGF for diabetic macular oedema(DMO) (n = 5) or choroidal neovascularisation (CNV) (n = 1). Four received ranibizumab whilst two (not known to be pregnant) received aflibercept. Patients known to be pregnant underwent counselling by an obstetric physician. Five pregnancies resulted in live births. Combining our cases with those previously published, treatment of 41 pregnant women (42 pregnancies) are reported. Indications for treatment included CNV (n = 28/41,68%), DMO (n = 7/41,17%) and proliferative diabetic retinopathy (n = 6/41,15%). Bevacizumab (n = 22/41,54%) and ranibizumab (n = 17/41,41%) were given more frequently than aflibercept (n = 2/41,5%). Many (n = 16/41,40%) were unaware of their pregnancy when treated. Most pregnancies resulted in live births (n = 34/42,81%). First trimester miscarriages (n = 5/42,12%) and stillbirths (n = 3/42,7%) mostly occurred in women with significant risk factors. Conclusion Intravitreal anti-VEGF injections may not necessarily compromise obstetric outcomes, although clear associations cannot be drawn due to small numbers and confounders from high rates of first trimester miscarriages in general and inherently high-risk pregnancies. It may be worth considering routinely investigating pregnancy and breastfeeding status in women of childbearing age prior to each injection, as part of anti-VEGF treatment protocols.

show abstract

Anti-VEGF (anti-vascular endothelial growth factor) treatment for central vein occlusion during breastfeeding

Cited by 2 publications

References 8 publications

Development and Evaluation of Potato Starch and Chitosan Modified Capecitabine Nanoparticles for Enhanced Colon Cancer Treatment: A Comprehensive Study on PhysicalProperties, In vitro Efficacy, and In vivo Targeting

Development and Evaluation of Potato Starch and Chitosan Modified Capecitabine Nanoparticles for Enhanced Colon Cancer Treatment: A Comprehensive Study on PhysicalProperties, In vitro Efficacy, and In vivo Targeting

Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature

Contact Info

Product

Resources

About